ClinicalTrials.gg
CompletedNCT04958226Updated Jan 25, 2024

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

A Phase 1 interventional study of Capivasertib and Midazolam in Solid Tumour, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This is an open-label, fixed-sequence study to evaluate the effect of capivasertib on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate. The PK of midazolam will be assessed when administered alone and in combination with repeated doses of capivasertib.

Read the detailed description

This is 2 part study: Part A and Part B. Part A of the study consists of a screening period and 3 treatment periods (midazolam alone, capivasertib alone, and midazolam + capivasertib). During Part A, the PK profile of midazolam will be determined with and without capivasertib.All participants will receive capivasertib treatment (4 days on/3 days off); however, at the Investigator's discretion, ER positive breast cancer patients may also receive fulvestrant in addition to capivasertib and midazolam. Participants completing Part A without disease progression or unacceptable toxicity, who are considered likely to continue to benefit from further capivasertib treatment (with or without certain standard of care treatment) in the opinion of the Investigator will enter Part B. Part B of the study consists of an extended treatment period with capivasertib, with or without certain standard of care treatment, followed by a 30-day safety follow-up.

Part A of the study may be extended to allow the administration of midazolam on a rescheduled Cycle 1 Day 8(C1D8) and Cycle 1 Day 12(C1D12 ) visit.

02

Conditions studied

  • Solid Tumour

Keywords

  • CYP3A inhibitor
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with documented evidence of locally advanced inoperable or solid tumours who may be suitable to receive capivasertib treatment.
  2. /World Health Organization performance status 0 to 1 and with minimum for 12 weeks.
  3. Participant should have at least one lesion that can be assessed by computed tomography/magnetic resonance imaging or plain X-ray at baseline.
  4. within the range 18 to 32 kg/m\^2

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Radiotherapy with a wide field of radiation within 4 weeks of the first dose of capivasertib and/or radiotherapy with a limited field of radiation for palliation within 2 weeks prior to study intervention initiation.
  2. Participants with diabetes mellitus type I or participants with diabetes mellitus type II requiring insulin treatment.
  3. Undergone a major surgery within 4 weeks of the first dose of capivasertib.
  4. Any unresolved toxicities from prior therapies higher than grade 2 or any unresolved toxicity that may interfere with PK assessment at the time of study intervention initiation.
  5. Participants with spinal cord compression or .
  6. Participants with severe or uncontrolled systemic diseases, active bleeding diatheses, or active infection.
  7. Previous bone marrow transplant or solid organ transplant.
  8. Known immunodeficiency syndrome.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment (Midazolam + Capivasertib)

    Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.

    Drug: Capivasertib · Drug: Midazolam

Interventions

  • Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.

  • Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.

06

What researchers measure

Primary outcomes

  1. Midazolam AUCinf

    Area under the plasma concentration-time curve from zero to infinity

    Time frame: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  2. Midazolam Cmax

    Maximum observed plasma (peak) drug concentration

    Time frame: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

Secondary outcomes

  1. Midazolam AUClast

    Area under plasma concentration-time curve from zero to the last quantifiable concentration

    Time frame: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  2. Midazolam t½λz

    Half-life associated with terminal slope (λz) of a semilogarithmic concentration-time curve

    Time frame: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  3. Midazolam tmax

    Time to reach peak or maximum observed concentration

    Time frame: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  4. Capivasertib Ctrough

    Observed lowest drug concentration reached before the next dose is administered

    Time frame: Cycle 1 Day 9 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  5. Capivasertib Cmax

    Maximum observed plasma (peak) drug concentration

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  6. Capivasertib AUCτ

    Area under plasma concentration-time curve in the dose interval

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  7. Capivasertib t½λz

    Half-life associated with terminal slope (λz) of a semilogarithmic concentration-time curve

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  8. Capivasertib tmax

    Time to reach peak or maximum observed concentration

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  9. Capivasertib CL/F

    Apparent total body clearance of drug from plasma after extravascular administration

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  10. Capivasertib metabolite AZ14102143 Ctrough

    Observed lowest drug concentration reached before the next dose is administered

    Time frame: Cycle 1 Day 9 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  11. Capivasertib metabolite AZ14102143 Cmax

    Maximum observed plasma (peak) drug concentration

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  12. Capivasertib metabolite AZ14102143 AUCτ

    Area under plasma concentration-time curve in the dose interval

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  13. Capivasertib metabolite AZ14102143 t½λz

    Half-life associated with terminal slope (λz) of a semilogarithmic concentration-time curve

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  14. Capivasertib metabolite AZ14102143 tmax

    Time to reach peak or maximum observed concentration

    Time frame: Cycle 1 Day 12 and Cycle 1 Day 13 (Cycle 1 is 29 days)

  15. Number of participants with adverse events and serious adverse events

    Assessment of safety and tolerability of capivasertib (with or without the use of standard of care)and in combination with midazolam.

    Time frame: From screening to disease progression or discontinuation from the study (up to 15 months)

07

Study locations

5 sites
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Dallas, Texas 75251, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Feb 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2021
First posted
Jul 12, 2021
StartActual
Oct 15, 2021
Primary completionActual
Feb 6, 2023
CompletionActual
Feb 15, 2023
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04958226
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 12, 2021
Start date
Oct 15, 2021
Primary completion
Feb 6, 2023
Completion
Feb 15, 2023
Last update
Jan 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capivasertib · Midazolam

Start the discussion